Clinical trial NCT02423408: Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
Official title: A Proof-of-Concept Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-201 for the Treatment of A Single Tension-Type Headache
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Tension-Type Headache
Lead sponsor: Tonix Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2015-04-22
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache (TTH).

Detailed description: The study will be conducted in 4 periods (the Screening Period, the Run-In Period, the Double-Blind Treatment Period and the Follow-up Period) and 4 visits (the Screening Visit, Enrollment Visit, Randomization Visit and End-of-Study Visit).

Screening Period- Eligible subjects who provide written informed consent to participate will have study assessments performed at the Screening.

Run-In Period- The Run-In Period will last for at least 28 days. During the Run-In period, subjects will be assessed for frequency of headache, study compliance and to ensure they meet all required study criteria for randomization.

Double-Blind Treatment Period- The Double-Blind Treatment Period (Treatment Period) will last up to 4 weeks or until a qualifying headache episode has occurred and been treated using the study drug, whichever occurs first.

Follow-up Period- All subjects will return to the investigational site for this visit, regardless of whether they have treated a qualifying TTH with study medication. Subjects who have not treated a qualifying TTH with study drug during the Treatment Period will be asked to return study materials and undergo safety evaluations at the End-of-Study Visit and will be discharged from the study. Subjects who have treated a qualifying TTH with study drug during the Treatment Period will ingest a 140 mg dose of open-label TNX-201 at this visit and undergo urine and blood sample collection for 3 hours post-dose to characterize each subject's genetic metabolism and PK profile.

Eligibility criteria: Inclusion Criteria:

1. Capable of reading and understanding English and able to provide written informed consent to participate.
2. Male or female adults ≥ 18 and \< 65 years of age at the time of Visit 1.
3. Body mass index (BMI) ≥ 18.5 and ≤ 45.0.
4. Greater than 1 year history of episodic tension-type headache with onset prior to 50 years of age.
5. History of tension-type headaches that typically last ≥ 4 hours if untreated.
6. History of 2-14 tension-type headaches per month for the last 3 months prior to Visit 1.
7. Diagnosis must comply with the International Headache Society (IHS) diagnostic criteria.
8. No significant ECG findings at Screening
9. If female, is either not of childbearing potential or is practicing a predefined medically acceptable method of birth control (hormonal methods, intrauterine device, double-barrier method, sexually-exclusive vasectomized male partner, same-sex relationship) throughout the study.
10. Willing and able to comply with all protocol-specified requirements.

Exclusion Criteria:

1. Known or suspected hypersensitivity to isometheptene mucate or any excipients used in the formulation.
2. Use of any excluded concomitant medications.
3. Current use of opiate analgesics.
4. Use of any prophylactic drug therapy for headache control within 4 weeks of screening (e.g., anticonvulsants, mood stabilizers, beta-blocker, antidepressants, muscle relaxants, botulinum toxin). Subjects taking any of these medications for an indication other than headache (e.g., a beta-blocker for hypertension) will require medical monitor's approval prior to initiation of the Run-In Period.
5. History of medication use for acute headache on ≥ 10 days per month on average during the 3 months prior to Visit 1.
6. Positive results for addictive substances (e.g., cocaine, phencyclidine (PCP), amphetamines, opiates) at Screening.
7. History of migraine that exceeds a mean of four attacks per month during the preceding calendar year.
8. Lifetime history of schizophrenia, schizoaffective disorder, bipolar I/II disorder, delusional disorder, or psychotic disorder not otherwise specified.
9. Chronic pain disorders requiring medical treatment with opioids, chronic daily use of NSAIDs at the time of screening
10. History of coronary artery disease, coronary vasospasm, aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud's syndrome).
11. Inadequately controlled hypertension or persistently elevated systolic blood pressure or diastolic blood pressure upon repeat assessment at screening or on the day of randomization.
12. Current history of two or more CAD risk factors at Screening (tobacco use, receiving anti-hypertensive medication for hypertension, high LDL cholesterol or low HDL cholesterol levels, family history of premature CAD, diabetes mellitus)
13. History cerebral vascular accident, transient ischemic attack, seizure disorders.
14. Other clinically significant cardiac disease.
15. History of concurrent illness that requires hospitalization within 30 days prior to Visit 1.
16. Current evidence of human immunodeficiency virus infection or clinically significant hepatitis B or C infection.
17. Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history.
18. Participation in another investigational trial during the 30 days prior to Visit 1 or during this trial. Subjects who have participated in non-interventional trials may be permitted to participate on a case-by-case basis after review with the Medical Monitor.
19. Women who are pregnant, breast-feeding, or planning to become pregnant during this trial.
20. Any other household member currently participating in a Tonix-sponsored study or family member or relative of investigative staff.
21. Any condition and/or medical history that would make the subject unsuitable for study participation and completion.

Primary outcomes:
measure: Number of Subjects Pain Free
timeFrame: 2 hours
Secondary outcomes:
measure: Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question)
timeFrame: 15, 30, 60, 90 minutes and 4 hours post-dose
measure: Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period
timeFrame: 24-hour post-dose period
measure: Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders)
timeFrame: 2 hours
Other outcomes:
Locations:
city: San Jose
country: United States
facility: James D. Wolfe, MD
state: California
city: DeLand
country: United States
facility: Avail Clinical Research LLC.
state: Florida
city: Stockbridge
country: United States
facility: Nathan Segall, MD, CPI
state: Georgia
city: Ann Arbor
country: United States
facility: Michigan Head-Pain Neurological Institute
state: Michigan
city: Minneapolis
country: United States
facility: Gary D. Berman, MD
state: Minnesota
city: Raleigh
country: United States
facility: John Rubino, MD
state: North Carolina
city: Winston-Salem
country: United States
facility: PMG Research of Winston-Salem, LLC.
state: North Carolina
city: Cleveland
country: United States
facility: Rapid Medical Research, Inc.
state: Ohio
city: Nashville
country: United States
facility: Stephan C. Sharp, MD
state: Tennessee
city: Norfolk
country: United States
facility: Duane G. Wombolt, MD
state: Virginia
Study officials:
affiliation: 1 513 579 9911 ext 2214
name: Tracie Ruther, M.S
role: STUDY_DIRECTOR
References: